BLOG > Publications & Citations > Aurora Kinase A inhibition favors CRISPR/Cas9 gene correction over knock-out
Authors: Wilbie D, Eising S, Amo-Addae V, Walther J, Bosman E, et al.
Source: PLOS ONE 20(9): e0332617.
We're delighted to share insights from a recent study entitled "Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out" published in PLOS ONE by Danny Wilbie et al.
They screened a library of oncological drug compounds to steer the DNA repair process towards precise gene correction (Homology-Directed Repair, HDR) following CRISPR-Cas9 editing. Their work successfully identified that inhibiting Aurora Kinase A with alisertib leads to a significant, over 4-fold increase in preferential gene correction over gene knock-out in HEK293T and Hepa 1-6 cells. This offers a promising strategy to improve the outcomes of CRISPR-based gene therapies.
Congratulations to all the authors on this excellent article!
Our Pro-DeliverIN CRISPR was used in this study to successfully deliver the CRISPR-Cas9 ribonucleoprotein (RNP) complex into the murine hepatoma Hepa 1-6 cell line for the gene editing experiments.
Read the article Pro-DeliverIN CRISPR
